Analysts’ Recent Ratings Updates for Viridian Therapeutics (VRDN)

by · The Cerbat Gem

Several analysts have recently updated their ratings and price targets for Viridian Therapeutics (NASDAQ: VRDN):

  • 12/3/2025 – Viridian Therapeutics is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
  • 12/3/2025 – Viridian Therapeutics was given a new $47.00 price target on by analysts at William Blair.
  • 11/24/2025 – Viridian Therapeutics was given a new $41.00 price target on by analysts at Truist Financial Corporation.
  • 11/24/2025 – Viridian Therapeutics is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $41.00 price target on the stock.
  • 11/8/2025 – Viridian Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
  • 11/6/2025 – Viridian Therapeutics had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $40.00 price target on the stock.
  • 11/6/2025 – Viridian Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $41.00 to $45.00. They now have an “outperform” rating on the stock.
  • 11/4/2025 – Viridian Therapeutics had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $61.00 price target on the stock.
  • 10/21/2025 – Viridian Therapeutics had its price target raised by analysts at Oppenheimer Holdings, Inc. from $32.00 to $36.00. They now have an “outperform” rating on the stock.
  • 10/8/2025 – Viridian Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In related news, Director Fairmount Funds Management Llc purchased 454,545 shares of the firm’s stock in a transaction on Thursday, October 23rd. The shares were acquired at an average cost of $22.00 per share, with a total value of $9,999,990.00. Following the purchase, the director directly owned 3,914,458 shares of the company’s stock, valued at approximately $86,118,076. This trade represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.65% of the stock is owned by corporate insiders.

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

Read More